0000000000054796

AUTHOR

Cord Sunderkötter

0000-0002-2929-145x

showing 12 related works from this author

Keratinocytes Determine Th1 Immunity during Early Experimental Leishmaniasis

2010

Experimental leishmaniasis is an excellent model system for analyzing Th1/Th2 differentiation. Resistance to Leishmania (L.) major depends on the development of a L. major specific Th1 response, while Th2 differentiation results in susceptibility. There is growing evidence that the microenvironment of the early affected tissue delivers the initial triggers for Th-cell differentiation. To analyze this we studied differential gene expression in infected skin of resistant and susceptible mice 16h after parasite inoculation. Employing microarray technology, bioinformatics, laser-microdissection and in-situ-hybridization we found that the epidermis was the major source of immunomodulatory mediat…

KeratinocytesCellular differentiationImmunology/Innate ImmunityInterleukin-1betaGene ExpressionInfectious Diseases/Skin InfectionsMiceT-Lymphocyte SubsetsLeishmania majorBiology (General)In Situ HybridizationOligonucleotide Array Sequence AnalysisSkinRegulation of gene expressionMice Inbred BALB CReverse Transcriptase Polymerase Chain ReactionCell DifferentiationImmunohistochemistryInterleukin-12MicrodissectionResearch ArticleQH301-705.5ImmunologyLeishmaniasis CutaneousBiologyMicrobiologyTh2 CellsImmune systemCutaneous leishmaniasisImmunology/Immunity to InfectionsVirologyGeneticsmedicineAnimalsDermatology/Skin InfectionsMolecular BiologyInterleukin 4Epidermis (botany)Interleukin-6Gene Expression ProfilingLasersTh1 CellsRC581-607medicine.diseasebiology.organism_classificationMice Inbred C57BLGene expression profilingDisease Models AnimalImmunology/Immune ResponseImmunologyOsteopontinParasitologyInterleukin-4Immunologic diseases. AllergyPLoS Pathogens
researchProduct

Travel‐associated infectious skin diseases

2020

Travelmedicine.medical_specialtybusiness.industryDermatologySkin DiseasesDermatologyInfectious skin diseasesHumansMedicineddc:610Skin Diseases InfectiousTravel-Related IllnessbusinessTravel MedicineJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Diagnosis and therapy of cutaneous and mucocutaneous Leishmaniasis in Germany

2011

The incidence of cutaneous and mucocutaneous Leishmaniasis (CL/MCL) is increasing globally, also in Germany, although the cases are imported and still low in number. The current evidence for the different therapies has many limitations due to lack of sufficient studies on the different Leishmania species with differing virulence. So far there is no international gold standard for the optimal management. The aim of the German joint working group on Leishmaniasis, formed by the societies of Tropical Medicine (DTG), Chemotherapy (PEG) and Dermatology (DDG), was to establish a guideline for the diagnosis and treatment of CL and MCL in Germany, based on evidence (Medline search yielded 400 artic…

Leishmaniasis Mucocutaneousmedicine.medical_specialtymedicine.medical_treatmentParomomycinCryotherapyDermatologyPharmacotherapyCutaneous leishmaniasisPregnancyGermanyparasitic diseasesmedicineHumansMiltefosineAntiparasitic Agentsbusiness.industryLeishmaniasismedicine.diseaseDermatologyLymphangitisPregnancy Complications ParasiticFemaleDermatologic AgentsbusinessFluconazolemedicine.drugJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

S1-Leitlinie Diagnostik und Therapie der kutanen und mukokutanen Leishmaniasis in Deutschland

2009

business.industryMedicineDermatologybusinessJournal der Deutschen Dermatologischen Gesellschaft
researchProduct

S3-Leitlinie "Diagnostik, Therapie und Nachsorge des Melanoms" - Kurzfassung

2013

Oncologymedicine.medical_specialtySkin Neoplasmsbusiness.industryMelanomaMedizinGuidelineDermatologymedicine.diseaseMedical OncologyText miningInternal medicineGermanymedicineHumansbusinessMelanomaFollow-Up Studies
researchProduct

Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-α2b: patients’ and doctors’ views

2011

Treatment of malignant melanoma with IFN-α has been associated with significant side-effects. The aim of this retrospective monocentric non-randomized study was first to evaluate the impact on quality of life (QOL) in 30 melanoma patients treated with once weekly 2 μg/kg PEG-IFN-α2b for 18 months, and second to examine whether there is a difference in patients' and physicians' perception of QOL. Data on QOL were collected by means of the EORTC QLQ-C30 questionnaire completed by the patient before consultation at baseline and every three months during treatment. A second questionnaire was filled out independently by the physician, based on the consultation and patient file. All data were rou…

AdultMalemedicine.medical_specialtyAdolescentEvery Three Monthsmedicine.medical_treatmentOnce weeklyDermatologyInterferon alpha-2Antiviral AgentsPolyethylene GlycolsYoung AdultAmbulatory careQuality of lifePegylated interferonHumansMedicineIn patientMelanomaAgedRetrospective StudiesAged 80 and overbusiness.industryMelanomaInterferon-alphaMiddle Agedmedicine.diseaseRecombinant ProteinshumanitiesChemotherapy AdjuvantQuality of LifePhysical therapyFemalebusinessAdjuvantmedicine.drugEuropean Journal of Dermatology
researchProduct

Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma

2011

Objective  The aim of this study was to evaluate the safety and efficacy profile of pegylated interferon α-2b (PEG-IFN α-2b) in combination with photochemotherapy (PUVA) in the treatment of cutaneous T-cell lymphoma (CTCL) in comparison with standard IFN α plus PUVA. Design  Retrospective cohort study over a period of 7 years. Patients and interventions  A total of 17 consecutive CTCL patients (stage IA–IV) were retrospectively analysed for toxicity and response rates associated with PEG-IFN α-2b (1.5 μg/kg weekly) plus PUVA (n = 9) or standard IFN α-2a (9 MIU 3×/week) plus PUVA (n = 8). Main outcome measures  Differences of response rates (complete/partial remission), progression-free surv…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentCutaneous T-cell lymphomaDermatologymedicine.diseaseDermatologyGastroenterologyDiscontinuationchemistry.chemical_compoundInfectious DiseaseschemistryPegylated interferonInternal medicinePUVA therapyToxicitymedicinebusinessProspective cohort studyAdverse effectPsoralenmedicine.drugJournal of the European Academy of Dermatology and Venereology
researchProduct

S1-Leitlinie zur Diagnostik und Therapie der kutanen Larva migrans (Creeping disease)

2014

DermatologyJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Interleukin 1α Promotes Th1 Differentiation and Inhibits Disease Progression in Leishmania major–susceptible BALB/c Mice

2003

Protective immunity against pathogens such as Leishmania major is mediated by interleukin (IL)-12–dependent Th1-immunity. We have shown previously that skin-dendritic cells (DCs) from both resistant C57BL/6 and susceptible BALB/c mice release IL-12 when infected with L. major, and infected BALB/c DCs effectively vaccinate against leishmaniasis. To determine if cytokines other than IL-12 might influence disease outcome, we surveyed DCs from both strains for production of a variety of cytokines. Skin-DCs produced significantly less IL-1α in response to lipopolysaccharide/interferon γ or L. major when expanded from BALB/c as compared with C57BL/6 mice. In addition, IL-1α mRNA accumulation in l…

CD4-Positive T-LymphocytesLipopolysaccharidedendritic cellT helper cell type 1/T helper cell type 2 immune responsemedicine.medical_treatmentImmunologyLeishmaniasis CutaneousMice Inbred StrainsLymphocyte ActivationArticleBALB/cMicechemistry.chemical_compoundCutaneous leishmaniasismedicineAnimalsImmunology and AllergyLeishmania majorLeishmania majorMice Inbred BALB CCD11b AntigenbiologyIL-1InterleukinDendritic Cellsbiology.organism_classificationmedicine.diseaseLeishmaniainfectionDisease Models AnimalCytokinechemistryImmunologyLymphInterleukin-1Journal of Experimental Medicine
researchProduct

DD ″Creeping eruption″

2015

Unter dem Begriff ″creeping eruption″ werden verschiedene Infektionen oder Infestationen gefuhrt. Hierunter fallen zum Beispiel wandernde subkutane Schwellungen mit Rotung und Urtikaria bei Gnathostomiasis, kutaner Paragonimiasis (Lungenegelinfektion) oder Fasziolose (Leberegelinfektion). Ahnliche wandernde Symptome sind auch bei Befall mit Fliegenmaden (″migratory myiasis″) moglich. Nicht alle derart bezeichneten Erkrankungen haben einen unmittelbaren Bezug zu Hauterscheinungen.

GynecologyPhysicsmedicine.medical_specialtymedicineCreeping eruption
researchProduct

Electrical impedance spectroscopy as a potential adjunct diagnostic tool for cutaneous melanoma.

2012

Background Previous studies have shown statistically significant differences in electrical impedance between various cutaneous lesions. Electrical impedance spectroscopy (EIS) may therefore be able to aid clinicians in differentiating between benign and malignant skin lesions. Objectives The aim of the study was to develop a classification algorithm to distinguish between melanoma and benign lesions of the skin with a sensitivity of at least 98% and a specificity approximately 20 per cent higher than the diagnostic accuracy of dermatologists. Patients/Methods A total of 1300 lesions were collected in a multicentre, prospective, non-randomized clinical trial from 19 centres around Europe. Al…

AdultMalemedicine.medical_specialtySkin NeoplasmsAdolescentDermatologySensitivity and SpecificityYoung AdultmedicineAtypiaPrevalenceHumansDiagnosis Computer-AssistedElectrical impedance spectroscopyMelanomaAgedAged 80 and overbusiness.industryMelanomaReproducibility of ResultsMiddle Agedmedicine.diseaseDermatologyClinical trialEuropeDielectric SpectroscopyCutaneous melanomaDysplastic nevusFeasibility StudiesFemaleSkin cancerbusinessSkin lesionAlgorithmsSkin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
researchProduct

LFA-1 Contributes to Signal I of T-Cell Activation and to the Production of Th1 Cytokines

2010

The beta(2) integrins are important for both transendothelial migration of leukocytes and T-cell activation during antigen presentation. In T cells, triggering of leukocyte functional antigen-1 (LFA-1) is required for full activation and T-helper (Th)1/Th2 differentiation. We used CD18-deficient (CD18(-/-)) mice to examine the role of LFA-1 in the activation of T cells. Compared with wild-type controls, CD18(-/-) T cells proliferated normally when stimulated with antibodies against CD3 and CD28, but secreted significantly less IFN-gamma and IL-2 than their wild-type counterparts. However, when T cells were stimulated with dendritic cells (DCs) that provide additional LFA-1 ligation, the pro…

CD3 ComplexT cellchemical and pharmacologic phenomenaDermatologyBiologyBiochemistryAntibodiesMinor Lymphocyte Stimulatory AntigensInterferon-gammaMice03 medical and health sciencesInterleukin 210302 clinical medicineCD28 AntigensCell AdhesionmedicineAnimalsCytotoxic T cellIL-2 receptorAntigen-presenting cellMolecular Biology030304 developmental biologyMice Inbred BALB C0303 health sciencesCD40CD28Cell Differentiationhemic and immune systemsDendritic CellsCell BiologyTh1 CellsIntercellular Adhesion Molecule-1Natural killer T cellLymphocyte Function-Associated Antigen-1Mice Mutant StrainsCell biologyMice Inbred C57BLmedicine.anatomical_structureCD18 Antigensbiology.proteinInterleukin-2Cell DivisionSignal Transduction030215 immunologyJournal of Investigative Dermatology
researchProduct